India has launched a groundbreaking cancer treatment that could potentially transform the administration of immunotherapy for lung cancer patients. Roche Pharma India has unveiled a new subcutaneous injection of its immunotherapy drug Tecentriq, which delivers treatment in just seven minutes. This innovative approach stands in contrast to the traditional intravenous infusions that typically require several hours in healthcare facilities.

This development is particularly significant for individuals diagnosed with non-small cell lung cancer (NSCLC), the predominant form of lung cancer in India. Healthcare professionals express that the reduced treatment duration may alleviate the burden of hospital crowding, enhance patient comfort, and provide a more manageable option for elderly patients or those who must travel long distances for therapy.

While there is considerable optimism surrounding this medical advancement, the accompanying high cost has sparked conversations among patients and families. Each dose of the new injection is priced at approximately Rs 3.7 lakh, and patients may require up to six doses, leading to a substantial financial burden on many households already facing escalating healthcare costs.

Understanding Tecentriq and Its Mechanism

Tecentriq contains atezolizumab, a drug designed to impede a protein known as PD-L1, which cancer cells often utilise to evade detection by the immune system. By blocking PD-L1, the drug enables immune cells to recognise cancer cells and initiate a targeted attack. Medical professionals indicate that this treatment is particularly beneficial for patients whose tumours exhibit elevated levels of PD-L1 expression.

Before commencing treatment, patients undergo testing to ascertain their potential benefit from this therapy. Experts assert that immunotherapy represents a significant evolution in cancer treatment modalities, as it typically results in fewer severe side effects compared to conventional chemotherapy and has demonstrated promising outcomes in decelerating cancer progression and enhancing survival rates among eligible patients.

The seven-minute injection is notable for its convenience, as patients previously had to dedicate hours to receive IV immunotherapy. The new method allows for administration beneath the skin, commonly in the thigh, and significantly shortens the overall time required for treatment. Such improvements can alleviate the physical and emotional strain patients endure during their cancer journey.

Eligibility and Financial Considerations

Currently, the injection targets patients suffering from non-small cell lung cancer, which constitutes the majority of lung cancer cases in India. However, not every patient is eligible for this treatment. Medical assessments are conducted to determine if the patient’s tumour has high levels of PD-L1 protein, as those with elevated levels are generally more likely to respond positively to the injection.

The therapy can be utilised either as a standalone treatment or in conjunction with other cancer therapies, depending on the patient’s overall health, the stage of the disease, and physician recommendations. Reports indicate that nearly half of NSCLC patients may qualify for this new treatment.

Despite its advantages, the financial implications of this therapy remain challenging, with each dose costing nearly Rs 3.7 lakh, making it unaffordable for many families. Though newer immunotherapy options are available globally at similar price points, Roche has initiated a patient support initiative called “Blue Tree” and has included Tecentriq in the Central Government Health Scheme (CGHS) to assist eligible patients with reimbursement options.

Healthcare experts advocate for broader insurance coverage, government intervention, and more cost-effective treatment strategies to enhance accessibility in India. Even with the concerns surrounding affordability, the introduction of the seven-minute cancer injection is acknowledged as a notable advancement in the country’s oncology landscape, with the potential to significantly improve the quality of life for lung cancer patients.

Long or Short, get news the way you like. No ads. No redirections. Download Newspin and Stay Alert, The CSR Journal Mobile app, for fast, crisp, clean updates!

App Store –  https://apps.apple.com/in/app/newspin/id6746449540 

Google Play Store – https://play.google.com/store/apps/details?id=com.inventifweb.newspin&pcampaignid=web_share